BTG Licenses Alzheimer's Compounds To Senexis And Co-Invests £1 Million With The Wellcome Trust
BTG plc and Senexis Limited announced that BTG has exclusively licensed its novel inhibitors of amyloid-induced toxicity and neuroinflammation to Senexis. These compounds may be useful in the treatment of Alzheimer's disease and other amyloid-based diseases. BTG will receive milestones payments as the compounds progress though development and future royalties on eventual sales. The first milestones will be triggered by candidate selection and approval to commence clinical studies.
BTG and the technology transfer division of the Wellcome Trust also announced that they have each invested £500,000 into Senexis to enable the company to progress preclinical development of its small molecule Alzheimer's programmes. BTG and the Wellcome Trust provided initial funding of £1.4 million to Senexis in November 2002.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
List_of_medical_specialty_colleges_in_the_United_States

Viral infections could drive neurodegeneration

M's Science Corporation - Kōbe, Japan

Rainin MicroPro | Mettler-Toledo

Enzyme inhibitor slows tumour growth - Research team discovers novel approach to treating certain B-cell lymphomas

GeneraMedix Inc. - Liberty Corner, USA

Covid vaccination improves effectiveness of cancer treatment - Clinical study on nasopharyngeal cancer with unexpected result
